文献速递肾移植

在肾移植受者中,基于肌酐而非胱抑素C估算的GFR更能反映低GFR不良结局的真实风险

GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究纳入1135例连续成人肾移植受者,于2011至2013年标准化评估GFR,随访至2020年。结果显示,eGFRcr较eGFRcys更能代表GFR与移植失败及心血管事件或死亡的真实关系,因其非GFR残余关联较少;胱抑素C在肾移植中宜作为非特异性预后生物标志物解读。

要点

  • eGFRcr较eGFRcys具有更少的非GFR残余关联,更真实反映GFR与结局的关系。
  • 校正mGFR后,eGFRcys仍与移植失败及心血管事件或死亡相关,而eGFRcr无此关联。
  • 胱抑素C在肾移植中宜解读为非特异性预后生物标志物。

核心结论

  • eGFRcr更好地代表了肾移植后GFR与结局之间的真实关系,因为其非GFR残余关联较少。
  • 在肾移植背景下,胱抑素C宜解读为非特异性预后生物标志物,而非eGFR。

研究设计与样本

  • 连续成人肾移植受者在2011至2013年常规随访门诊期间接受标准化GFR评估。
  • 随访至2020年,观察移植失败或心血管事件与死亡的复合结局。
  • 共纳入1135例受者,基线平均mGFR为55.6 ml/min/1.73 m2、eGFRcr为54.8 ml/min/1.73 m2、eGFRcys为46.8 ml/min/1.73 m2,中位随访6年。

主要发现

  • mGFR、eGFRcr或eGFRcys每降低10 ml/min/1.73 m2,与移植失败相关(HR分别为1.79、1.68和2.07,P均<.001)。
  • mGFR、eGFRcr或eGFRcys每降低10 ml/min/1.73 m2,与心血管事件或死亡结局相关(HR分别为1.28、1.19和1.43,P均<.001)。
  • 校正mGFR后,eGFRcys与移植失败相关(HR 1.57,P<.001)及与心血管事件或死亡相关(HR 1.49,P<.001),但eGFRcr与两者均无关联。
  • 进一步校正心血管危险因素后,较低eGFRcys与这些结局的风险关联减弱。

关键数值与推荐

  • mGFR、eGFRcr或eGFRcys每降低10 ml/min/1.73 m2与移植失败相关:HR分别为1.79、1.68和2.07(P均<.001)。
  • mGFR、eGFRcr或eGFRcys每降低10 ml/min/1.73 m2与心血管事件或死亡相关:HR分别为1.28、1.19和1.43(P均<.001)。
  • 校正mGFR后,eGFRcys与移植失败相关:HR 1.57(P<.001);与心血管事件或死亡相关:HR 1.49(P<.001);eGFRcr与两者均无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum cystatin C-based estimated glomerular filtration rate (eGFRcys) generally associates with clinical outcomes better than serum creatinine-based eGFR (eGFRcr) despite similar precision in estimating measured GFR (mGFR). We sought to determine whether the risk of adverse outcomes with eGFRcr or eGFRcys was via GFR alone or also via non-GFR determinants among kidney transplant recipients. METHODS: Consecutive adult kidney transplant recipients underwent a standardized GFR assessment during a routine follow-up clinic visit between 2011 and 2013. Patients were followed for graft failure or the composite outcome of cardiovascular (CV) events or mortality through 2020. The risk of these events by baseline mGFR, eGFRcr and eGFRcys was assessed unadjusted, adjusted for mGFR and adjusted for CV risk factors. RESULTS: There were 1135 recipients with a mean baseline mGFR of 55.6, eGFRcr of 54.8 and eGFRcys of 46.8 ml/min/1.73 m2 and a median follow-up of 6 years. Each 10 ml/min/1.73 m2 decrease in mGFR, eGFRcr or eGFRcys associated with graft failure [hazard ratio (HR) 1.79, 1.68 and 2.07, respectively; P < .001 for all) and CV events or mortality outcome (HR 1.28, 1.19 and 1.43, respectively; P < .001 for all). After adjusting for mGFR, eGFRcys associated with graft failure (HR 1.57, P < .001) and CV events or mortality (HR 1.49, P < .001), but eGFRcr did not associate with either. After further adjusting for CV risk factors, risk of these outcomes with lower eGFRcys was attenuated. CONCLUSION: eGFRcr better represents the true relationship between GFR and outcomes after kidney transplantation because it has less non-GFR residual association. Cystatin C is better interpreted as a nonspecific prognostic biomarker than is eGFR in the kidney transplant setting.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Keddis MT, Howard MR, Galapia L, et al. GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients. Nephrol Dial Transplant. 2023. PMID: 36646435. doi:10.1093/ndt/gfad007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。